- Home
- FI vs GSK Comparison
FI vs GSK Comparison
Compare FI & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FI
- GSK
- Stock Information
- Founded
- FI 1984
- GSK 1715
- Country
- FI United States
- GSK United Kingdom
- Employees
- FI N/A
- GSK N/A
- Industry
- FI Business Services
- GSK Biotechnology: Pharmaceutical Preparations
- Sector
- FI Consumer Discretionary
- GSK Health Care
- Exchange
- FI Nasdaq
- GSK Nasdaq
- Market Cap
- FI 95.0B
- GSK 77.1B
- IPO Year
- FI 1986
- GSK N/A
- Fundamental
- Price
- FI $139.63
- GSK $40.19
- Analyst Decision
- FI Strong Buy
- GSK Hold
- Analyst Count
- FI 27
- GSK 2
- Target Price
- FI $213.77
- GSK N/A
- AVG Volume (30 Days)
- FI 4.8M
- GSK 3.8M
- Earning Date
- FI 07-23-2025
- GSK 07-30-2025
- Dividend Yield
- FI N/A
- GSK 4.03%
- EPS Growth
- FI 3.45
- GSK N/A
- EPS
- FI 5.97
- GSK 1.13
- Revenue
- FI $21,112,000,000.00
- GSK $43,336,073,439.00
- Revenue This Year
- FI $4.64
- GSK $5.56
- Revenue Next Year
- FI $8.08
- GSK $5.08
- P/E Ratio
- FI $23.40
- GSK $35.46
- Revenue Growth
- FI 6.73
- GSK 0.59
- 52 Week Low
- FI $128.22
- GSK $31.72
- 52 Week High
- FI $238.59
- GSK $44.67
- Technical
- Relative Strength Index (RSI)
- FI 42.12
- GSK 63.65
- Support Level
- FI $131.64
- GSK $36.75
- Resistance Level
- FI $140.42
- GSK $40.55
- Average True Range (ATR)
- FI 2.77
- GSK 0.54
- MACD
- FI 1.84
- GSK 0.28
- Stochastic Oscillator
- FI 91.56
- GSK 90.05
About FI Fiserv Inc.
Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Through the merger with First Data in 2019, Fiserv also provides payment processing services for merchants. About 10% of the company's revenue is generated internationally.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.